IQV · Q3 2025 Earnings

Bullish

IQVIA

Reported October 28, 2025

30-second summary

IQVIA delivered $4.1B in Q3 revenue (+5.2% YoY) at the top of its prior guide, with R&DS book-to-bill at 1.15x, backlog at a record $32.4B, and free cash flow of $772M — the highest quarterly FCF in the company's history. RFP flow accelerated to +20% YoY (from low-teens last quarter), and management initiated Q4 guidance implying 6.2–8.7% revenue growth — a meaningful acceleration from Q3's 5.2%. The catch: FY25 EPS and EBITDA ranges were narrowed by clipping the high end (FY EPS upside cut from $12.05 to $11.95; FY EBITDA upside cut from $3,825M to $3,800M) while midpoints held — a subtle hedge on Q4 execution that the press release tone doesn't acknowledge.

Headline numbers

EPS

Q3 FY2025

$3.00

Revenue

Q3 FY2025

$4.10B

+5.2% YoY

Gross margin

Q3 FY2025

33.5%

Free cash flow

Q3 FY2025

$0.77B

Operating margin

Q3 FY2025

13.5%

Key financials

Q3 FY2025

Metric	Q3 FY2025	YoY	Q2 FY2025	QoQ
Revenue	$4.10B	+5.2%	$4.02B	+2.1%
EPS	$3.00	—	$2.81	+6.8%
Gross margin	33.5%	—	32.9%	+60bps
Operating margin	13.5%	—	12.6%	+90bps
Free cash flow	$0.77B	—	$0.29B	+164.4%

Guidance

FY2025 guidance ranges tightened at midpoints held; Q3 beat prior expectations; Q4 forward guidance shows accelerating revenue and EPS growth driven by RFP momentum and AI demand.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Revenue	Q3 FY2025	$4,025 million to $4,100 million	$4,100 million	at high end of guide	Beat
Adjusted EPS	Q3 FY2025	$2.92 to $3.02	$3.00	at midpoint of guide; within range	Beat
Adjusted EBITDA	Q3 FY2025	$935 million to $955 million	$949 million	within range	Met

New guidance

Metric	Period	Guide	YoY
Revenue	Q4 FY2025	$4,204 million to $4,304 million	6.2% to 8.7%
Adjusted EPS	Q4 FY2025	$3.35 to $3.45	7.4% to 10.6%
Adjusted EBITDA	Q4 FY2025	$1,033 million to $1,058 million	3.7% to 6.2%

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Revenue	FY2025	$16,100 million to $16,300 million	$16,150 million to $16,250 million	midpoint flat at $16.2B, but range narrowed; low end raised $50M, high end lowered $50M	Lowered
Adjusted EPS	FY2025	$11.75 to $12.05	$11.85 to $11.95	$11.9B midpoint stable, but range compressed by $0.30 ($0.10 low, $0.10 high); narrowed	Lowered
Adjusted EBITDA	FY2025	$3,750 million to $3,825 million	$3,775 million to $3,800 million	low end raised $25M to $3,775M; high end lowered $25M to $3,800M; midpoint stable ~$3,787.5M	Lowered

Segment KPIs

Q3 FY2025

Segment	Q3 FY2025	YoY
Research & Development Solutions (R&DS)	$2.26B	+4.5%
Technology & Analytics Solutions (TAS)	$1.631B	+5.0%
Contract Sales & Medical Solutions (CSMS)	$0.209B	+16.1%

Other KPIs

Q3 FY2025

Segment	Q3 FY2025
R&DS Contracted Backlog	$32.4 billion
R&DS Contracted Backlog YoY Growth	4.1%
Net New Bookings (R&DS)	$2.6 billion
Book-to-Bill Ratio	1.15x
12-Month Backlog Conversion	$8.1 billion
Adjusted EBITDA	$949 million
Operating Cash Flow	$908 million
Free Cash Flow YoY Growth	35%

Management tone

Q1 anchor unknown → Q2 "see more, win more" with margin honesty → Q3 demand acceleration with selective margin discipline.

RFP flow went from recovery to acceleration. Last quarter management framed RFP growth as "low-teens YoY" and said R&DS was inflecting on every leading indicator. This quarter it's "+20% YoY with growth across all segments" — and Evercore's Anderson got management to confirm large-pharma cancellations have normalized from a 2024 peak (>$3B in cancellations) to a steady-state ~$550M/quarter. The verbatim line: "RFP flow growth sequentially and 20% growth year-over-year with growth across all segments." Two quarters ago this was a recovery story; this quarter it's a normalized-demand story with biotech funding adding tailwind. That's a different bull case.

AI moved from agents-in-production to a deployment roadmap. Q2 disclosed "20+ AI agents in production" with 50+ queued. Q3 disclosed "90 agents in development covering 25 use cases" with a target of "500 specialized agents by early 2027." The cadence is faster than last quarter implied. Management also reframed the client-side story: "we are now seeing growing demand to help our clients accelerate AI adoption." That's a pivot from internal productivity to external revenue narrative — though still without quantified margin or pricing impact, which Stephens' Garrow pushed on and management deflected.

Free cash flow language went from competent to assertive. Q2 free cash flow was $292M and discussed in working-capital terms. Q3 was $772M (+35% YoY) and management framed it as "the highest quarterly free cash flow ever, even when you consider the large advances we got during the COVID era for vaccine trials." Beating COVID-era cash flow as a comparison point is a deliberate flex — and it's accurate.

Margin commentary became selectively defensive. Q2 management was explicit that mix headwinds "persist the next couple of quarters" and decomposed the compression. Q3 gross margin recovered 60bps QoQ to 33.5%, validating the cyclical framing — but management cut the FY EBITDA and EPS high ends anyway, and FY EBITDA growth guidance (2.5–3.1%) remains well below revenue growth (4.8–5.5%). The shift: management is no longer apologizing for margin, they're managing expectations. The "selective reinvestment in AI and CSMS" framing is a more confident way of saying the same thing as Q2's mix-compression decomposition.

On CSMS, the tone shifted from line-item to strategic pillar. CEO explicitly: "We decided to increase our capabilities in this segment as we are seeing a developing trend of large pharma clients increasingly looking to outsource commercial operations." Last quarter CSMS was the smallest, fastest-growing segment in a table. This quarter it's a strategic capability build with an acquisition (Acuvia) and a thesis about large-pharma outsourcing durability.

Recurring themes management leaned on this quarter:

Clinical demand acceleration and bookings strengthAI-enabled solution deployment and client adoptionOutsourced commercial operations expansionRecord backlog and improving customer decision timelinesStrong free cash flow generationDrug launch momentum in commercial segment

Risks management surfaced:

COVID-related revenue step-down of approximately $100M in R&D solutionsForeign exchange headwinds (partially offset by 100bps tailwind in guidance)Customer decision-making timeline improvements still sequential—not uniformly acceleratedExecution risk on deploying 90 AI agents across 25 use casesMargin compression risk from selective reinvestment in AI and CSMS

Q&A highlights

David Windley · Jefferies

How has the 'see more, win more' strategy contributed to RFP flow improvements and win rate, and what pricing competitiveness is being applied in this strategy and its P&L implications?

The strategy targets previously untouched markets where smaller players had quasi-monopolies. Early pricing discounts were aligned to market conditions but have normalized—management walked away from deals in recent quarters. With a $32+ billion backlog and only marginal discounts earlier in the year, no P&L impact is expected over the next five years.

$32+ billion backlogOnly tiny portion of backlog subject to early-year discountsManagement walked away from deals in recent quartersPricing has returned to normal levels

Elizabeth Anderson · Evercore ISI

What are the differences between pharma and biotech dynamics, particularly regarding large pharma's investment programs and pipeline reprioritization activity?

Large pharma completed major reprioritization and cancellations (driven by IRA) by mid-2024; cancellations were >$3 billion in 2024 vs. normal $500-700M/quarter baseline. These are now normalized to ~$550M/quarter. RFP flow for large pharma is strong (+20% YoY), and pipelines are 'sanitized.' Biotech funding is improving, driving RDS growth. Bookings grew 13% YoY with $2.6B net bookings.

2024 cancellations: >$3 billion (vs. normal $500-700M/quarter)YTD cancellations: ~$550M/quarter averageRFP flow growth: 20% YoY (applies equally to large pharma and EBP)Net bookings: $2.6B, up 13% YoY

Shlomo Rosenbaum · Stifel

What are the sub-component growth rates within TAS (real world evidence, consulting, analytics) and what do these trends indicate about market conditions?

Q3 had tough comparables (6% growth in Q3 2023). Real world evidence was very strong; consulting turned positive (after being negative in late 2023/early 2024), and other components grew in low-to-mid single digits. Consulting is a leading indicator of market health—it declined sharply when sentiment was negative and is now recovering.

Q3 2024 TAS growth tough vs. Q3 2023 (6% prior year)Real world evidence: very strong growthConsulting: returned to positive (was negative double-digits in late 2023/early 2024)Other TAS components: low-to-mid single digit growth

Eric Caldwell · Baird

Q4 TAS revenue guidance specificity—February guidance of $6.3-6.5B for full year TAS appears inconsistent with YTD performance, suggesting potential miss vs. street consensus. Also, status on two mega trials and IQVIA's Phase 1 expansion strategy.

Management maintains 5-6% FX-adjusted TAS growth guidance with no changes all year; reaffirmed there are no changes to TAS full-year landing. On mega trials: neither trial is contemplated in Q4 guidance (both pushed out of the year). Phase 1 expansion underway as part of 'see more, win more' with network partnerships; Phase 1 oncology is differentiated due to patient population.

TAS FX-adjusted growth guidance: 5-6% (unchanged all year)Two mega trials: not in Q4 guidance, both pushed to 2025+No revenue impact from trial delays in full-year 2024 guidancePhase 1 oncology expansion ongoing via Next Oncology acquisition (acquired end Q3)

Jeff Garrow · Stephens

How is AI changing customer business models and outsourcing appetite? How is IQVIA using AI internally to improve margins and efficiency?

IQVIA has 90 AI agents in development covering 25 use cases; targeting 500 specialized agents by early 2027. Internal use cases show cycle time improvements (weeks to weeks reduction) and gross margin upside longer-term. Clients use AI in discovery (molecule screening), patient insights, real-world data analysis, and promotional campaign management. Regulatory constraints limit clinical AI deployment to intermediary spaces between regulatory interactions.

90 AI agents in development, 25 use cases currentlyTarget: 500 specialized agents by early 2027Cycle time improvements: from weeks to 1-2 weeks (example given)AI enables 'doing more with less' in internal processes

Answers to last quarter's watch list

R&DS book-to-bill sustaining above 1.10x. Resolved positively. Q3 printed 1.15x (vs. 1.12x in Q2), net new bookings stepped to $2.6B (from $2.5B), and backlog grew to $32.4B (from $32.1B). Every metric moved the right direction. Status: Resolved positively.

Gross margin trough timing. Q3 gross margin recovered 60bps QoQ to 33.5% from 32.9%, validating the cyclical-not-structural framing. The trough appears to have been Q2. That said, FY EBITDA guidance growth of 2.5–3.1% remains well below revenue growth of 4.8–5.5%, so the margin pressure isn't fully gone — just stabilized. Status: Resolved positively.

FSP share of backlog stabilizing at 16–17%. The company didn't disclose updated FSP share of backlog on this print. With margin recovering 60bps QoQ, the framing is consistent with stabilization, but the specific data point wasn't called out. Status: Continue monitoring.

Large delayed trial restart in late 2025. Resolved negatively. In Q&A, management confirmed neither of the two mega trials is contemplated in Q4 guidance — "both pushed out of the year." Management says full-year delivery is intact regardless, but the specific Q4 step-up framed last quarter as trial-driven didn't materialize. Status: Resolved negatively.

AI agent deployment count. Resolved positively. Management said in Q2 there would be "50+ additional agents, 15 use cases" by Q3; the actual disclosure is 90 agents in development across 25 use cases, with a 500-agent target by early 2027. Pace exceeded the guide. Margin quantification still absent, however. Status: Resolved positively (count), Continue monitoring (margin impact).

EBP win-rate sustainability vs. pricing. Resolved positively. Jefferies' Windley pushed directly on pricing and management said only a "tiny portion" of backlog was subject to early-year discounts, pricing has returned to normal, and they've walked away from deals. Combined with bookings of $2.6B and book-to-bill of 1.15x, the share gains are holding without ongoing price concessions. Status: Resolved positively.

What to watch into next quarter

Q4 revenue landing within the 6.2–8.7% YoY guide. Hitting the midpoint or better validates the demand-acceleration narrative; landing at the low end would suggest the RFP-to-revenue conversion is slower than the +20% RFP growth implies. The high-end clip on FY EBITDA hints management isn't fully confident.

TAS reacceleration in Q4. Q3 TAS decelerated to +5.0% from Q2's +8.9% on a tough comp. Management held FY TAS growth of 5–6% FX-adjusted, which requires Q4 TAS to be at least in line with Q3. Anything below 5% breaks the FY framing and reopens questions about consulting durability.

FY26 framing on the Q4 print. Management deflected 2026 questions this quarter, offering only "at least the same or better" than 2024. Watch whether the Q4 print includes a concrete FY26 framing and whether RFP growth and backlog conversion translate into a guide above the 5.2% FY25 midpoint.

Free cash flow durability after the record Q3. $772M (+35% YoY) is exceptional but includes working-capital tailwind management called "good and disciplined." Watch whether Q4 sustains the run-rate or whether working capital reverses.

AI revenue and margin quantification. Management has now disclosed counts (90 → 500 by 2027) twice without any pricing, revenue, or margin specifics. The next credible step is a disclosed AI-related revenue contribution or a specific gross margin uplift. Until then, the AI story is operational, not financial.

CSMS organic growth ex-Acuvia. Reported +16.1% / +13.9% constant currency includes the Acuvia acquisition. The strategic outsourcing thesis requires organic CSMS to sustain double-digit growth. Watch the disclosed organic split.

Sources

IQVIA Q3 2025 earnings press release (SEC filing): https://www.sec.gov/Archives/edgar/data/1478242/000162828025046554/iqv-q3x2025earningspressre.htm
IQVIA Q3 2025 earnings call commentary (referenced in transcript-derived guidance and Q&A extracts)
Tapebrief IQV Q2 2025 brief (prior-quarter watch list and guidance baseline)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.